Home / Oligonucleotides and Peptides
Oligonucleotides & Peptides
From a screening sequence to commercial supply, on one platform.
The volume behind it
We deliver more than 100,000 oligonucleotides and more than 50,000 peptides a year, from milligram screening quantities to commercial batches.
More than 2,300 scientists at WuXi TIDES work only on oligonucleotides and peptides. The modalities demand it: coupling efficiency, epimerization, purification economics and impurity resolution all behave differently from small molecule chemistry, and the differences show at scale.
16 molecules through process validation, none failed
Process performance qualification is the stage that confirms a process is ready for commercial production.
Since 2019 we have run more than 30 PPQ campaigns and taken 16 new chemical entities through qualification with a 100 percent success rate — across fragments, linear peptides, peptide-drug conjugates, radionuclide-drug conjugates and peptide-PMO.
Discovery
Drug Substance
Drug Product
Integrated Services
Oligonucleotides
ASO, siRNA, sgRNA, PMO, PPMO and aptamers, including chirally controlled designs, heavily modified backbones and constructs up to 158 mer. We support 126 oligonucleotide molecules across preclinical to commercial stages: 73 siRNA, 25 ASO, 21 PMO and PPMO, 6 sgRNA and tRNA, and one aptamer.
Critical amidites and ligands are made in-house, including more than 100 GalNAc structures and more than 40 catalog amidites at commercial scale with Drug Master Files already filed. For an oligonucleotide program, that keeps critical raw material inside the platform.
Peptides
Linear, cyclic, modified and conjugation-ready peptides, on more than 20 solid-phase production lines with vessels from 10 litres to 5,000 litres. More than 330 peptides supported from preclinical through Phase II since 2018: over 200 linear, 80 cyclic and 50 conjugates.
Commercial peptide manufacture runs at a process mass intensity of 85 per amino acid against a published industry average of 875, roughly a tenfold reduction in material consumed per unit of product.
Conjugates
We support 118 peptide- and oligonucleotide-based conjugates from preclinical to commercial: 45 oligonucleotide-GalNAc, 28 radionuclide drug conjugates, 18 peptide-oligonucleotide including peptide-PMO, 10 antibody-oligonucleotide, 9 peptide-drug and 8 oligonucleotide-lipid.
A conjugate needs three components made and then joined: the peptide or oligonucleotide, the payload or ligand, and the linker. The payload chemistry is small molecule work, and here it happens in the same organization, so a peptide-oligonucleotide conjugate, which needs both platforms and a shared analytical group, runs as one program.
Inspection history
Across WuXi STA and WuXi TIDES:
Two further plants are under construction at Taixing for 2027, and one at Singapore for the second quarter of 2028.
20
12
95
17
4
6
450+
Your complex challenges. Our precise solutions.
The molecules that define the field now are harder to make: a conjugate that needs three chemistries, a 158-mer that stepwise synthesis cannot reach, an oral peptide that has to survive the gut. That is the chemistry this platform is built for.
Specialty chemistry makes them feasible and manufacturing scale makes them suppliable, and both sit in one organization.
Move fast. Move forward.